title: [Successful treatment with rituximab in a patient with refractory mixed-type autoimmune hemolytic anemia].
abstract: The evidence that rituximab is effective therapy for refractory warm or cold autoimmune hemolytic anemia (AIHA) has been accumulating; however, the efficacy of rituximab for mixed-type AIHA is not evident. Herein, we report a case of mixed-type AIHA refractory to corticosteroids and splenectomy, but successfully treated with rituximab (375 mg/m(2)/day, once weekly, four times). She achieved a complete response, which has been maintained for 16 months, to date, despite steroid tapering. Our case suggests that rituximab therapy should be considered for refractory AIHA even of mixed-type.
authors.affiliation: Department of Medical Oncology and Hematology, Sapporo Medical University.
authors.forename: Kaoru
authors.initials: K
authors.lastname: Ono
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Sato
authors.forename: Satoshi
authors.initials: S
authors.lastname: Iyama
authors.forename: Ayumi
authors.initials: A
authors.lastname: Tatekoshi
authors.forename: Akari
authors.initials: A
authors.lastname: Hashimoto
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Kamihara
authors.forename: Hiroto
authors.initials: H
authors.lastname: Horiguchi
authors.forename: Shohei
authors.initials: S
authors.lastname: Kikuchi
authors.forename: Kohichi
authors.initials: K
authors.lastname: Takada
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Hayashi
authors.forename: Koji
authors.initials: K
authors.lastname: Miyanishi
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Sato
authors.forename: Rishu
authors.initials: R
authors.lastname: Takimoto
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Kobune
authors.forename: Junji
authors.initials: J
authors.lastname: Kato
mesh_terms: D000744:Anemia, Hemolytic, Autoimmune / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D012074:Remission Induction / Q000379:methods; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab